Exco InTouch’s ePRO Seminars Highlight Growing Importance of Electronic Communication in Clinical Trials
News Jun 04, 2009
Exco InTouch has announced that the company’s recent Electronic Patient Reported Outcomes (ePRO) seminars highlighted the increasing shift from traditional methods of data collection in clinical trials towards electronic methods.
The informative seminars entitled ‘The Complete Patient Experience Throughout the Trial Lifecycle’ took place in Philadelphia and London and demonstrated the benefits of using electronic technology for patient recruitment, retention and compliance during clinical trials.
The half-day seminars were co-hosted by Exco InTouch and ERT, a leading provider of centralized ECG and eClinical technology, ePRO and other services to the biopharmaceutical, medical device and related industries. Seminars in both London and Philadelphia venues were attended by over 40 delegates from small, medium and large pharma organizations and CRO companies.
The seminars addressed the impact of new communication technologies on patient engagement in clinical trials and how these technologies have revolutionized data collection for pharmaceutical companies.
Several industry leaders attended the seminars to conduct discussions on the application of these methods for clinical trials, including a keynote address from Dr. Ken Kaitin, Director and Professor of Medicine Tufts Center for the Study of Drug Development at Tufts University, Massachusetts.
Dr. Kaitin is an internationally recognized expert on the science of drug development processes in the pharmaceutical and biopharmaceutical industries. His address entitled ‘Pharmaceutical Innovation at a Cross Roads: Economic and Political Perspectives on New Drug Development Process’, explored the current economic, regulatory, and political challenges in developing new pharmaceutical products.
Representatives from global pharmaceutical companies also participated in the seminars including Mahnaz Asgharnejad, VP of Clinical Development at CeNeRx BioPharma, a biopharmaceutical company developing innovative treatments for diseases of the central nervous system. Dr. Asgharnejad discussed the application of ePRO to facilitate patient selection and monitoring in clinical trials.
During the seminars, Exco InTouch’s representatives demonstrated through numerous case studies how their innovative portfolio of communication-based technologies benefits pharmaceutical companies by improving patient recruitment, retention and compliance throughout the clinical trials process.
The seminars highlighted how using methods of electronic communication to retrieve confidential patient information improves the speed, accuracy and integrity of data. Several large pharmaceutical companies already employ Exco InTouch’s cell phone-based technology as a simple way to retrieve data from patients while maintaining full compliance with strict industry regulations.
Safety and Efficacy of MERS Treatment Confirmed in Phase I TrialNews
An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.READ MORE
Alzheimer’s Drug Discovery Foundation Announces $1.8M in New FundingNews
The Alzheimer’s Drug Discovery Foundation (ADDF) announces nearly $1.8 million in new funding, which reflects a commitment to advancing drugs in or near human clinical trials. All five funded programs are potential treatments for Alzheimer’s disease and other forms of dementia.READ MORE
£70M Meant for Cancer Drug Development is Reassigned to Prepare for BrexitNews
At the end of last year, the Health Committee held a meeting to discuss Brexit, more specifically the impact this will have on the discovery, development and regulation of medicines, medical devices and biopharmaceuticals.READ MORE